Pemetrexed for Chordoma

"Since 2007, Genzyme (a Sanofi Company) has been investigating the efficacy of pemetrexed through clinical trials. After a trial involving 698 patients in 2007, it was approved for Phase 3 drug use and is currently being studied at 225 sites spanning 74 countries and 2395 cities."

"Unfortunately, this trial has reached its recruitment capacity and is not looking for additional participants. It was initially announced on September 6th 2019 and last modified in August 5th 2022. However, 26 trials involving chordoma are enrolling patients while 225 studies related to Pemetrexed have open registration windows."

"Pemetrexed has been found to be efficacious in treating ovarian cancer as well as unresectable thymomas, mesotheliomas, and non-small cell lung cancers with a localised presentation."

"The safety of Pemetrexed is estimated to be a 1 according to our team at Power, as this is just an initial trial with limited data regarding its efficacy and security."

"Currently, 225 clinical trials researching Pemetrexed have been launched. Of these, 87 are in the third phase of testing and 19466 locations around the world are conducting studies for this treatment. Winston-Salem in North carolina is hosting most of them."

"Unfortunately, this trial is not presently seeking candidates. First published on September 6th 2019 and updated most recently as of August 5th 2022, it is currently inactive. However, there are 26 trials with chordoma research still recruiting participants, in addition to 225 studies utilizing Pemetrexed that have active recruitment processes."